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Role of the Transcriptional Repressor BCL6 in
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Abstract: Various molecules participate in different phases of
allergic reactions. This means that many genes are encoding
molecules related to allergic reactions, such as cytokines, chemo-
kines, and their receptors as effector molecules. The transcriptional
repressor BCL6 has emerged as a multifunctional regulator of
lymphocyte differentiation and immune responses. BCL6-deﬁcient
(BCL6j/j) mice display T helper type 2 (Th2)Ytype inﬂammation,
which is caused by abnormality of both lymphoid cells and
nonlymphoid cells. Thus, BCL6 apparently contributes to negative
regulation of various central molecules such as cytokines, in
particular Th2 cytokines, CC chemokines, and immunoglobulin E
in allergic diseases. Therefore, BCL6 may be a molecular target for
Th2-type allergic diseases.
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A llergic diseases are characterized by elevated serumimmunoglobulin E (IgE) levels and hypersensitivity to
normally innocuous antigens (allergens). A particular direct
allergen ﬁrst encounters antigen-processing cells such as
dendritic cells (DCs) or macrophages. The allergen is captured
by the antigen-processing cells, processed, and presented to
CD4+ T cells. CD4+ T cells are polarized into T helper type 1
(Th1) cells, producing interferon-F and interleukin 2 (IL-2),
and Th2 cells, producing IL-4, IL-5, IL-6, IL-10, and IL-13.
Interleukin 4 and IL-13 stimulate immunoglobulin class
switching, leading to the production of IgE, which binds to
its high-afﬁnity receptor (FcDRI) on the surface of mast cells or
basophils. The association of captured allergens with IgE
bound to FcDRI on the cell surface activates signal transduc-
tion in the cells and rapidly leads to the release of
inﬂammatory cytokines and chemical mediators, such as
histamine and leukotrienes. The Th2-type cytokines also
trigger the production of chemokines in tissue ﬁbroblasts or
epithelial cells, promoting the inﬁltration of inﬂammatory
cells into sites exposed to allergens.
Various allergy-related molecules are basically con-
trolled by transcriptional regulators, critical molecules
believed to govern the pathogenesis of allergic diseases by
regulating cytokine production, mediator synthesis, and IgE
production at gene expression levels. Recent genetic studies
have demonstrated that transcriptional factors and regulators
are involved in the development of allergic diseases. The
molecular mechanisms of allergic diseases, in particular
bronchial asthma, are gradually becoming clearer. However,
nearly all previous studies of transcriptional factors have
focused on active regulators, including GATA binding protein
3 (GATA3), signal transducer and activator of transcription 6
(STAT6), c-Maf, NF-AT, NF-JB, and c-fos. The functional
roles of transcriptional repressors in allergic diseases remain
poorly understood. Because transcriptional repressors may
have an important role in tuning physiologically optimal
transcription, functional failure of tightly controlled constitu-
tive mechanisms regulated by a given repressor may lead to the
development of allergic diseases.
A transcriptional repressor gene, BCL6, has emerged as
a multifunctional regulator of lymphocyte differentiation and
immune responses.1,2 BCL6 mutant mice display two
prominent phenotypes: failure to form germinal centers during
T cellYdependent immune responses and fatal eosinophilic
inﬂammatory diseases characterized by the presence of Th2
cells and mast cells.3Y5 Although the molecular mechanisms
underlying these phenotypes are largely unknown, studies in
BCL6-deﬁcient mice have suggested that BCL6 functions to
prevent the development or attenuate the pathogenesis of
allergic diseases. In this article, we review the functions of
BCL6 in allergic diseases by focusing on recent data from our
laboratories and from other groups.
STRUCTURE AND BASIC FUNCTIONS OF BCL6
The human proto-oncogene BCL6 was ﬁrst identiﬁed in
studies of chromosomal breakpoints involving 3q27 in diffuse
large B-cell lymphomas.6Y8 BCL6 is expressed at low levels in
a wide variety of tissues. It is expressed abundantly only in
germinal center B cells, cortical thymocytes, and parafollicular
T cells within secondary lymphoid tissues.9 High BCL6 levels
are also present in cells of monocytic lineage.10 The BCL6
gene encodes a 92- to 98-kd nuclear phosphoprotein that
contains the BTB/POZ domain in the NH2-terminal region and
Kru¨ppel-type zinc ﬁnger motifs in the COOH-terminal region
(Fig. 1). Because the NH2-terminal half of BCL6 can bind to
silencing mediator of retinoid and thyroid receptor protein
(SMRT) and recruit the SMRT/histone deacetylase complex to
silencer regions of target genes to repress the expression of
these genes, BCL6 can function as a sequence-speciﬁc
REVIEW ARTICLE
WAO Journal & July 2008 115
Received for publication March 28, 2008; accepted April 25, 2008.
From the *Department of Developmental Genetics, Chiba University Graduate
School of Medicine, Chiba; and †Department of Pulmonary Medicine and
Clinical Immunology, Dokkyo University School of Medicine, Dokkyo,
Japan.
The authors declare no conflict of interest.
Reprints: Takeshi Fukuda, Department of Pulmonary Medicine and Clinical
Immunology, Dokkyo University School of Medicine, 880 Mibu-machi
Shimotsuga-gun, Tochigi 321-0293, Japan. E-mail: t-fukuda@
dokkyomed.ac.jp
Copyright * 2008 by World Allergy Organization
transcriptional repressor. The BCL6 zinc-ﬁngers bind to DNA
in a sequence-speciﬁc manner, and a consensus BCL6 DNA-
binding site has been identiﬁed.11,12 The BCL6 consensus
binding site resembles the GAS motif recognized by the STAT
family of transcription factors, raising speculation that BCL6
may bind competitively to some STAT-binding sites to repress
expression of STAT-dependent genes.3,13,14 Target genes of
BCL6 have been identiﬁed. Available evidence indicates that
BCL6 is a multipotential molecule because its target genes are
related to various molecules, including cytokines, chemokines,
cell cycle regulators,DNAdamageY related proteins, apoptosis-
related proteins, and transcriptional factors (Fig. 2).3,15Y31
When overexpressed, BCL6 can inhibit cell growth and
even induce programmed cell death in nonlymphoid cells such
as ﬁbroblasts.32,33 This ﬁnding indicates that BCL6 is toxic to
cells that do not normally express the protein at high levels.
Although this fact suggests an important role of BCL6 in
normal cell growth, its relevance to normal cell physiology is
unclear. We have recently demonstrated that BCL6 is essential
for the generation of high-afﬁnity memory B cells in germinal
centers4,34 and that BCL6 controls the generation and
maintenance of memory CD8+ T cells35,36 and memory CD4
T cells.37 Our ﬁndings suggest that Bcl6 in T cells plays a role
in protecting memory precursor T cells from apoptosis and
may be involved in the survival of long-term memory T cells.
FUNCTIONS OF BCL6 IN B CELLS
Although BCL6 messenger RNA (mRNA) can be
detected in many tissues,38 its protein expression is limited
mainly to lymphocytes.38Y40 BCL6 expression is strongly
induced in splenic B cells stimulated with IL-4 or IL-21.41
Although IL-2 and IL-7 mediate their biological effects
through a common cytokine receptor gamma chain, which is
shared with receptors for IL-4 and IL-21, stimulation with
these cytokines did not induce high BCL6 expression in
splenic B cells. Kinetic analysis demonstrated that BCL6
expression was transiently induced in B cells 30 minutes after
stimulation with IL-4 or IL-21. BCL6 expression was further
induced in these activated B cells within 6 hours after stim-
ulation with IL-21. In contrast, the recurrence of IL-4Yinduced
BCL6 expression was delayed, occurring 24 hours after
stimulation. These ﬁndings suggested that IL-4 and IL-21
might be required for high BCL6 expression in B cells
at different stages. Stimulation of splenic B cells with IL-4 or
IL-21 induced high BCL6 expression with activation of
STAT6 or STAT3, respectively, and binding of these STATs
to the STAT/BCL6-binding sites in the BCL6 promoter was
detected in germinal center B cells in mice. Interleukin 4 and
IL-21 may thus have physiological roles in promoting high
BCL6 expression in germinal center B cells, and BCL6 induced
by STATs activated with IL-4 and/or IL-21 might autoregulate
its promoter by negative feedback inhibition.
BCL6 can repress the IL-4Ydependent induction of
immunoglobulin germ line transcripts by STAT6. Consistent
with the role of BCL6 in modulating transcription from the
germ line promoter, BCL6j/jmice display an increased ability
to class switch to IgE in response to IL-4 in vitro.30,31 These
animals also exhibit a multiorgan inﬂammatory disease
characterized by the presence of large numbers of IgE+ B
cells. The apparent regulation of IgE production is abolished in
STAT6j/jBCL6j/j mice, indicating that BCL6-dependent
regulation of immunoglobulin class switching is STAT6
dependent. Thus, BCL6 can modulate the transcription of
selective STAT6-dependent IL-4 responses, including IgE
class switching in B cells. Furthermore, we recently simulta-
neously stimulated activated B cells with IL-4 and IL-21 and
found that expression of CFN germ line transcript (for IgG1
class switching) in BCL6 wild type (Wt) and BCL6j/j B cells
was enhanced by IL-21 stimulation, indicating that IL-21 is an
enhancer of CFN expression induced by IL-4.42 The amount of
CFN germ line transcript in the BCL6j/j B cells was greater
than that in the BCL6-Wt B cells. Conversely, IL-21 stim-
ulation suppressed C? (for IgE class switching) expression
in the BCL6-Wt B cells. In contrast, such suppression
was not observed in the BCL6j/j B cells, suggesting that
the IL-21Ymediated suppression of C?. expression is caused by
BCL6. Thus, BCL6 controls CFN and C? expression and
stabilizes class switching to IgG1 in activated B cells simul-
taneously stimulated with IL-4 and IL-21.
CD23, also known as Fc epsilon RII or FcDRII, is the
low-afﬁnity receptor for IgE. This antibody isotype is involved
in allergy and resistance to parasites and has an important role
in the regulation of IgE levels. Unlike many other antibody
FIGURE 1. Structure of BCL6. The BCL6 gene encodes a 92- to 98-kd nuclear phosphoprotein that contains the BTB/POZ
domain in the NH2-terminal region and Kru¨ppel-type zinc ﬁnger motifs in the COOH-terminal region. The NH2-terminal half of
BCL6 can bind to SMRT and recruit the SMRT/histone deacetylase complex to silencer regions of target genes to repress the
expression of these genes. Because the BCL-6 zinc-ﬁngers bind DNA in a sequence-speciﬁc manner, BCL6 can function as a
sequence-speciﬁc transcriptional repressor.
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receptors, CD23 is a C-type lectin. It is found on not only
mature B cells, but also activated macrophages, eosinophils,
follicular DCs, and platelets. BCL6 also binds to the STAT6
DNA-binding sequence in the CD23b promoter to repress
IL-4Yinduced activation of CD23 expression.3 Therefore,
BCL6 may be involved in the control of IgE production and
act as a negative regulator on one of its ligands.
ROLES OF BCL6 IN T-CELL FUNCTION
BCL6j/j mice show inﬂammatory responses in multi-
ple organs, especially the heart and lung, characterized by
eosinophil inﬁltration in young adults.3,5,41,43 BCL6 is
considered to regulate Th2-cell differentiation and/or Th2
cytokine production after differentiation. Several groups have
investigated the roles of Th2-cell function.
Similar to the key regulators T-bet for Th1 and GATA3
for Th2, human BCL6 was differentially and reciprocally
regulated during early Th1- and Th2-cell polarization. At the
protein level, the expression of BCL6 was barely detectable in
T-helper precursor cells. At the mRNA level, BCL6 is
preferentially expressed in cells induced to polarize in the
Th1 direction. BCL6 is expressed within 6 hours, and are
maintained for at least 48 hours. In contrast, a low level of
BCL6 expression is seen in cells induced to polarize in the Th2
direction, apparently because IL-4 down-regulates the human
BCL6 gene at an early stage.44,45 The differences in BCL6
between Th1- and Th2-polarization decreased or vanished
48 hours after each skewing.
Similar to human BCL6 during the early stage of
differentiation into helper T cells, murine BCL6 protein is
rapidly induced in naive T cells induced to polarize in the Th1
FIGURE 2. Target genes of BCL6. Previous studies indicate that BCL6 acts as a multipotential molecule because its target genes are
for various molecules, including cytokines, chemokines, cell cycle regulators, DNA damageYrelated proteins, apoptosis-related
proteins, and transcriptional factors. ATR indicates ataxia telangiectasia and Rad3 related; IP10, interferon-inducible protein 10;
MIP-1>, macrophage inﬂammatory protein 1>; MRP-1, macrophage inﬂammatory proteinYrelated protein 1; PDCD2, programmed
cell death 2.
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direction, whereas it is induced at a much lower level in T cells
skewed toward the Th2 phenotype rather than the Th1
phenotype. The induction of early BCL6 gene expression
was transient. Interestingly, Th2-skewed cells showed reinduc-
tion of BCL6 at a moderately higher level than Th1-skewed
cells did within 7 days during the differentiation of each cell
type.46 We also found that BCL6 protein was transiently
degraded in polarized Th2 cells by T-cell receptorYmediated
restimulation, followed by another transient increase in BCL6
protein after 24 hours. In addition, BCL6 gene expression was
inhibited by antiYIL-4 antibodies in polarized Th2 cells after
restimulation. Thus, IL-4 may have a bipotential effect and
attenuate as well as augment BCL6 production. The machinery
for down-regulation of BCL6 remains unclear, whereas its up-
regulation might involve STAT6-mediated activation of BCL6
promoter in B cells. Furthermore, autoregulation of BCL6
promoter by negative feedback inhibition may occur subse-
quently, as seen in B cells. Therefore, IL-4 may participate
physiologically in the differentiation and reactivation of Th2
cells by tuning the expression of BCL6, which functions on
target gene by competing with STATs.
Differentiation of the Th2 pathway has a critical role in
determining the outcomes of immune responses. Mediators of
Th2 differentiation have been partly elucidated and include a
number of cytokines and related signaling molecules. Antigen
triggering of naive T cells in the presence of IL-4 generates a
Th2 response. Interleukin 4Yinduced gene activation in the
Th2 response is mediated by STAT6.47 Dent et al48 have
shown that IL-4j/jBCL6j/j and STAT6j/jBCL6j/j
double-mutant mice have the same Th2-type inﬂammation
of the heart and lungs as that characteristically occurring in
BCL6j/j mice. Furthermore, the Th2 cytokine response that
develops in STAT6j/jBCL6j/j and IL-4j/jBCL6j/j mice
is similar to that in BCL6j/j mice after immunization with a
conventional antigen in adjuvant. In contrast to these in vivo
ﬁndings, STAT6 was required for the in vitro differentiation
of BCL6j/j T cells into Th2 cells. BCL6 can bind to similar
DNA-binding motifs as STAT transcription factors, suggest-
ing that BCL6 regulates Th2 responses in vivo through a
pathway(s) unrelated to IL-4 and STAT6. Kusam et al16 have
investigated the mechanism of BCL6 regulation during Th2-
cell differentiation in vitro and have found that IL-6 signaling
can promote dramatically increased levels of Th2 differentia-
tion in BCL6j/j CD4 T cells, as compared with BCL6-Wt
CD4 T cells. Interleukin 6 could induce Th2 cytokine ex-
pression in STAT6j/jBCL6j/j cells, but not in BCL6j/j
cells. They also studied whether GATA3 levels are up-
regulated in STAT6j/jBCL6j/j CD4 T cells as compared
with STAT6j/j CD4 T cells. Retrovirus-mediated expression
of BCL6 in both STAT6j/jBCL6j/j and BCL6-Wt T cells
led to a signiﬁcant decrease in GATA3 protein levels,
thought to be regulated at a post-transcriptional level. Thus,
overproduction of Th2 cytokines by BCL6j/j T cells cannot
be explained by loss of competitive inhibition of STAT6 ac-
tivity, and the regulation of GATA3 protein levels by BCL6
is probably a key mechanism by which BCL6 regulates
STAT6-independent Th2 cytokine expression and Th2 dif-
ferentiation. The factors that control this alternative pathway
have yet to be identiﬁed.
In vitro Th2 cells that have differentiated from BCL6-Wt
and BCL6j/j naive T cells produce cytokines other than IL-5
at similar levels after activation, respectively. Interleukin 5 is
an important Th2 cytokine involved in controlling the growth,
differentiation, and activation of eosinophils,49 which densely
inﬁltrate peripheral tissues in BCL6j/j mice. Because
production of IL-5 by BCL6j/j T cells was augmented in
vivo and in vitro, we have investigated whether BCL6-related
mechanisms regulate IL-5 production, and have identiﬁed
a BCL6-binding DNA sequence as a silencer (IL5BS) in the 3¶
untranslated (3¶UT) region of the murine and human IL-5
genes.15
As described above, regulation of IL-4 production by in
vitroYdifferentiated Th2 cells is most likely not regulated by
BCL6. However, we have identiﬁed putative multiple BCL6-
binding sites in the IL-4 gene, and BCL6 binds to these sites at
rest but not after activation (M. Arima, MD, PhD, et al,
unpublished data, 2008). The physiological roles of BCL6 in
lymphocytes with respect to Th2-cell differentiation and the
functions of BCL6 such as cytokine production thus remain to
be determined.
ROLES OF BCL6 IN CHEMOKINE PRODUCTION
Toney et al19 have suggested that the development of
Th2-type inﬂammation depends on BCL6 deﬁciency in some
nonlymphoid tissues. They found that three chemokines,
monocyte chemoattractant protein 1 (MCP-1), MCP-3, and
macrophage inﬂammatory proteinYrelated protein 1, were
induced at higher levels in BCL6j/j macrophages than in
their BCL6-Wt counterparts. Furthermore, they identify three
potential BCL6-binding sites in the promoter of each
chemokine. Recently, we found that production of chemo-
kines, including MCP-1, was regulated in airway epithelial
cells and macrophages by BCL6. Many CC-type chemokine
genes are located in a gene cluster at chromosomes 17q11.2
and 11q21.2 in humans and mice, respectively. The cluster
includes genes encoding CCL2 (MCP-1) -CCL7 (MCP-3) -
CCL11 (eotaxin) -CCL8 (MCP-2) -CCL13 (MCP-4) -CCL1
(I-309) in humans and CCL2-CCL7-CCL11-CCL12 (MCP-5)
-CCL8-CCL1 in mice. The strong similarity in the clusters
between humans and mice strongly suggests that chemokine
expression is orchestrated by the conserved machinery.
Because MCP-1 (CCL2) is known to be negatively regulated
by BCL6 and some putative BCL6-binding sequences are
observed in the gene clusters, we examined the role of BCL6
in the expression of these chemokine genes in the cluster. The
levels of these chemokine mRNAs other than CCL12 mRNA
were strikingly higher in lung tissues and bronchoalveolar
lavage ﬂuid cells from BCL6j/j mice than in those from
control mice. Down-regulation of BCL6 in human alveolar
epithelial cells (A549) up-regulated the expression of these
chemokine genes. Furthermore, chromatin modiﬁcations, such
as acetylation andmethylation of histone, and BCL6 binding to
the sequences in the cluster were observed in each cell line on
chromatin immunoprecipitation assay (T. Seto, MD, PhD,
et al., unpublished data, 2008). These results suggest that
BCL6 promotes Th2 differentiation via other mediators, such
as chemokines, in addition to IL-4. This notion is supported by
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evidence that MCP-1 stimulates IL-4 production by T cells,50
MCP-1j/j mice show very poor Th2 differentiation,51 and
MCP-1 also suppresses IL-12 secretion from human peripheral
blood monocytes.52 Thus, BCL6 may play an important role in
the coordinated regulation of these chemokine genes in
pulmonary epithelial cells and macrophages. BCL6 apparently
acts as a transcriptional repressor not only for Th2-cell
functions, but also for migration of inﬂammatory cells,
including eosinophils, macrophages, and mast cells. These
cells also contribute to Th2-type inﬂammation and/or Th2-cell
differentiation by producing Th2-type cytokines.
FUNCTIONS OF BCL6 IN MACROPHAGES
BCL6 has been reported to play an important role in the
functions of macrophages, as described previously. Further-
more, we have recently identiﬁed other effects of BCL6 on IL-
18 production in macrophages. Interleukin 18 was discovered
as a potent interferon-FYinducing factor that is produced by
macrophages and DCs in response to stimulation with
microbes or microbe products.53 Recent studies have shown
that IL-18 can also promote Th2 cytokine production from T
cells, natural killer cells, basophils, and mast cells.54,55
Interleukin 18 seems to be involved in human allergic diseases
such as atopic dermatitis (AD), bronchial asthma, and rhinitis.
Several studies have reported correlations among serum levels
of IL-18, IgE, and disease severity in AD and asthma.56Y59
Furthermore, leukocytes prepared from the peripheral blood of
patients with AD produce larger amounts of IL-18 in response
to lipopolysaccharide (LPS) than do leukocytes from healthy
volunteers.60 Interleukin 18 levels in nasal secretions are also
higher in patients with allergic rhinitis than in healthy
volunteers.61
Because IL-18 triggers the differentiation of Th2 cells,
we examined the expression of IL-18 mRNA in bone
marrowYderived macrophages from BCL6j/j mice after
LPS stimulation.17 The expression of IL-18 was strikingly
up-regulated after stimulation. The expression was also up-
regulated in RAW264 cells, a murine macrophage cell line, by
transfection with the dominant negative type ofBCL6 gene.We
identiﬁed a putative BCL6-binding DNA sequence (IL-18BS)
upstream of exon 1 of the murine IL-18 gene and three IL-
18BSs in the promoter region of the human IL-18 gene.
Binding of BCL6 in nuclear protein from resting RAW264
cells to murine IL-18BS was detected on gel retardation assay
and chromatin immunoprecipitation assay. The binding
activity decreased gradually in RAW264 cells after LPS
stimulation. However, the amount of BCL6 protein in these
cells remained constant over the period examined, suggesting
the functional modiﬁcation of BCL6 protein after stimulation.
Furthermore,murine IL-18BSwas required forBCL6 to repress
the expression of the luciferase reporter gene under control of
the IL-18 promoter. Therefore, BCL6 might be a key regulator
of IL-18 production by macrophages in allergic diseases.
ROLES OF BCL6 IN MAST CELLS
Mast cells are distributed throughout vascularized
tissues and play a key role in allergic reactions by releasing
proinﬂammatory mediators. Mast cellYderived factors act on
immune-competent cells to promote survival of eosinophils,
maturation of DCs, and activation of B and T cells by
producing cytokines such as Th2 cytokines and chemokines
such as MCP-1,62Y66 macrophage inﬂammatory protein 1>,
regulated on activation normal T-cell expressed and secreted
(RANTES), and eotaxin, which foster Th2 development and
eosinophil recruitment.67 Available evidence thus suggests
that mast cells are an initiator of Th2-type inﬂammation in
BCL6j/j mice. We have therefore investigated the properties
and functions of BCL6j/j mast cells derived from bone
marrow cells cultured with IL-3 (BMMCs). There was no
signiﬁcant difference between BCL6j/j BMMCs and BCL6-
Wt BMMCs in the expression of surface FcR1 or c-Kit, in
apoptosis induced by deprivation of IL-3, or in degranulation.
However, BCL6j/j BMMCs stimulated by FcRI/IgE cross-
linking expressed greater amounts of mRNAs of Th2 cytokines
such as IL-4, IL-5, and IL-13 than BCL6-Wt BMMCs did.
Because Th2 cytokines, including IL-4 and IL-13, have an
important role in Th2 development,68,69 mast cells may be one
of the initiators of Th2 dominance in BCL6j/j mice. Because
the number of intraepithelial mast cells increased in BCL6j/j
mice19 and the production of Th2 cytokines was augmented in
activated BCL6j/j mast cells, BCL6j/j mast cells may also
be a major effector of Th2-type inﬂammation in BCL6j/j
mice. Thus, BCL6j/j mast cells are one of the initiators of
Th2-type inﬂammation in BCL6j/j mice.
ROLES OF BCL6 IN ASTHMA
Interestingly, some BCL6-regulated genes are represen-
tative genes implicated in allergic diseases. These genes are
critical to the pathogenesis of allergic diseases such as asthma
and pollinosis. Recently, we studied the roles of BCL6 in T
cells in the development of asthma. To this end, Lck promoter-
controlled BCL6 transgenic (Lck-BCL6-Tg) mice and
BCL6-Wt mice were sensitized with intraperitoneal injec-
tions of ovalbumin. Fourteen days after the antigen challenge,
isolated Th2 cells (T1ST2 positive) were stimulated with
anti-CD3 antibody. Production of IL-4 by T1ST2 T cells
from Lck-BCL6 Tg mice was signiﬁcantly attenuated as
compared with that by BCL6-Wt mice, indicating that Th2
cytokine production was inhibited by BCL6 in T cells
(T. Ogasawara, MD, PhD, et al, unpublished data, 2008). We
also investigated the effect of T cells overexpressing BCL6
on the development of asthma by transferring splenic CD4 T
cells from sensitized mice into nontreated BCL6-Wt B6
mice. Twenty-four hours later, these mice were challenged
with ovalbumin. Antigen-induced eosinophilic airway inﬂam-
mation was observed after transfer of lymphocytes from
sensitized BCL6-Wt mice, associated with an elevated IL-4
level in bronchoalveolar lavage ﬂuid after antigen exposure.
The airway response and increased IL-4 production were
prevented by transfer of lymphocytes from sensitized Lck-
BCL6 Tg mice (T. Ogasawara, et al, unpublished data, 2008).
Therefore, BCL6 may prevent the development of asthma by
attenuating Th2 cytokine production in an experimental
murine model, and failure of BCL6 repressor activity may be
involved in the initiation and/or exacerbation of asthma in
humans.
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To test the hypothesis that variants of the BCL6 gene
might be associated with atopic diseases, Adra et al70
conducted a large-scale association study in both British (n =
275) and Japanese (n = 400) subjects. To identify the exact
localization of the known HindIII polymorphism in the ﬁrst
intron of the BCL6 gene (7 Kb), they ﬁrst fully sequenced the
7 Kb clone and determined primer sequences ﬂanking the
HindIII polymorphism. They analyzed relations between
different types of atopic phenotypes (distinguished by serum
IgE levels) and BCL6 genotypes. Variants of the BCL6 gene
were found to be signiﬁcantly associated with marked atopy,
characterized by high IgE levels and positive radioallergo-
sorbent test scores (93) to both house-dust mite and grass
pollen mixtures. However, the functions of the variant of
BCL6 remain unclear.
CONCLUSIONS
In allergic diseases, IL-4Ycontrolled transcriptional
regulatory processes might be physiologically regulated by
dual molecules, including activators such as STATs and
repressors such as BCL6. This control mechanism can be
likened to the concept of Byin and yang,[ involving two primal
opposing, but complementary principles. This concept is
plausible and critical for preserving biological homeostasis, in
which BCL6 may participate in resetting genetic activity. For
example, because Th2 cells secrete IL-4 and favor humoral
immunity to extracellular pathogens,71 BCL6 might attenuate
the response. Given that a failure of immune homeostasis
leads to the development of allergic diseases, BCL6 may play
an important part in such diseases, acting as an inhibitor or
protector. Thus, an imbalance between STAT6 and BCL6 may
be critically involved in the development of allergic diseases
because BCL6 contributes to the function of a wide range of
cells, including T cells, B cells, macrophages, mast cells, and
airway epithelial cells (Fig. 3). In these cells, BCL6 contributes
to the negative regulation of various key genes that predispose
patients to allergies. Therefore, BCL6 may be a major
molecular target for Th2-type allergic diseases. However,
many important questions remain unresolved, despite con-
siderable progress in understanding gene regulation by BCL6.
Further genetic and functional analyses are needed to clarify
whether BCL6 is related to the pathogenesis of allergic
diseases, with the ultimate goal of establishing more effective
means of prophylaxis and therapy. We hope that the studies
presented in this review will provide new insights into allergic
diseases.
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